The National Comprehensive Cancer Network, an organization best known for its clinical practice guidelines and its compendium, has quietly made a name for itself as a facilitator of industry-funded academic research. The most recent participant in NCCN's Oncology Research Program is GlaxoSmithKline. The group announced July 27 that the U.K.-based pharma giant had granted the program $4 million with which to fund exploratory clinical research on two compounds: ofatumumab, approved as Arzerra to treat...